DMAC - CIK 0001401040
DiaMedica Therapeutics Inc. (DMAC) reported net income of -$32.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$32.77M | -34.0% |
| FY 2024 | -$24.44M | -26.1% |
| FY 2023 | -$19.38M | -41.7% |
| FY 2022 | -$13.68M | -0.6% |
| FY 2021 | -$13.59M | -10.6% |
| FY 2020 | -$12.29M | -15.4% |
| FY 2019 | -$10.65M | -85.7% |
| FY 2018 | -$5.73M | -34.6% |
| FY 2017 | -$4.26M |
DiaMedica Therapeutics Inc. (DMAC) reported net income of -$32.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, DiaMedica Therapeutics Inc.'s net income declined from -$4.26M to -$32.77M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |